Sentinel lymph node biopsy as the new standard of care in the surgical treatment for breast cancer

Alberta Ferrari, Francesca Rovera, Paolo Dionigi, Giorgio Limonta, Marina Marelli, Isabella Besana Ciani, Veronica Bianchi, Cristiana Vanoli, Renzo Dionigi

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

During the recent years, based on the results of validation studies, the sentinel lymph node biopsy has replaced routine axillary dissection as the new standard of care in early breast cancer. The technique represents a minimally invasive, highly accurate method for axillary staging, which could spare approximately 65-70% of patients unnecessary axillary dissection and its related morbidity Several technical and clinical controversies have been raised during the development of this new technique; the authors review the most important issues, some questions have already been answered and others are still under debate. As far as the technical aspects are concerned, mapping techniques, appropriate surgical training, options for pathological examination of sentinel lymph nodes and the issue of nonaxillary sentinel lymph nodes are discussed. An update on clinical controversies demonstrates that factors such as large tumor size, palpable axillary nodes, multifocality and multicentricity, previous breast and axillary surgery, and pregnancy are no longer regarded as absolute contraindications for sentinel lymph node biopsy. Feasibility, accuracy and timing of sentinel lymph node biopsy in patients undergoing neoadjuvant chemotherapy remain unsolved issues, as well as the indication of the technique for some subgroups of in situ lesions. Finally, one of the most attractive open forums for debate will be discussed: Whether or not completion of axillary dissection in the case of positive SLN is always required.

Original languageEnglish
Pages (from-to)1503-1515
Number of pages13
JournalExpert Review of Anticancer Therapy
Volume6
Issue number10
DOIs
Publication statusPublished - Nov 2006

Fingerprint

Sentinel Lymph Node Biopsy
Standard of Care
Dissection
Breast Neoplasms
Validation Studies
Breast
Therapeutics
Morbidity
Drug Therapy
Pregnancy
Neoplasms
Sentinel Lymph Node

Keywords

  • Breast cancer
  • Breast surgery
  • Clinical controversies
  • Sentinel node biopsy
  • Sentinel node micrometastasis
  • Technical controversies

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

Sentinel lymph node biopsy as the new standard of care in the surgical treatment for breast cancer. / Ferrari, Alberta; Rovera, Francesca; Dionigi, Paolo; Limonta, Giorgio; Marelli, Marina; Ciani, Isabella Besana; Bianchi, Veronica; Vanoli, Cristiana; Dionigi, Renzo.

In: Expert Review of Anticancer Therapy, Vol. 6, No. 10, 11.2006, p. 1503-1515.

Research output: Contribution to journalArticle

Ferrari, Alberta ; Rovera, Francesca ; Dionigi, Paolo ; Limonta, Giorgio ; Marelli, Marina ; Ciani, Isabella Besana ; Bianchi, Veronica ; Vanoli, Cristiana ; Dionigi, Renzo. / Sentinel lymph node biopsy as the new standard of care in the surgical treatment for breast cancer. In: Expert Review of Anticancer Therapy. 2006 ; Vol. 6, No. 10. pp. 1503-1515.
@article{d680b2c0e10c4c7a954b11ff94fa8c51,
title = "Sentinel lymph node biopsy as the new standard of care in the surgical treatment for breast cancer",
abstract = "During the recent years, based on the results of validation studies, the sentinel lymph node biopsy has replaced routine axillary dissection as the new standard of care in early breast cancer. The technique represents a minimally invasive, highly accurate method for axillary staging, which could spare approximately 65-70{\%} of patients unnecessary axillary dissection and its related morbidity Several technical and clinical controversies have been raised during the development of this new technique; the authors review the most important issues, some questions have already been answered and others are still under debate. As far as the technical aspects are concerned, mapping techniques, appropriate surgical training, options for pathological examination of sentinel lymph nodes and the issue of nonaxillary sentinel lymph nodes are discussed. An update on clinical controversies demonstrates that factors such as large tumor size, palpable axillary nodes, multifocality and multicentricity, previous breast and axillary surgery, and pregnancy are no longer regarded as absolute contraindications for sentinel lymph node biopsy. Feasibility, accuracy and timing of sentinel lymph node biopsy in patients undergoing neoadjuvant chemotherapy remain unsolved issues, as well as the indication of the technique for some subgroups of in situ lesions. Finally, one of the most attractive open forums for debate will be discussed: Whether or not completion of axillary dissection in the case of positive SLN is always required.",
keywords = "Breast cancer, Breast surgery, Clinical controversies, Sentinel node biopsy, Sentinel node micrometastasis, Technical controversies",
author = "Alberta Ferrari and Francesca Rovera and Paolo Dionigi and Giorgio Limonta and Marina Marelli and Ciani, {Isabella Besana} and Veronica Bianchi and Cristiana Vanoli and Renzo Dionigi",
year = "2006",
month = "11",
doi = "10.1586/14737140.6.10.1503",
language = "English",
volume = "6",
pages = "1503--1515",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "10",

}

TY - JOUR

T1 - Sentinel lymph node biopsy as the new standard of care in the surgical treatment for breast cancer

AU - Ferrari, Alberta

AU - Rovera, Francesca

AU - Dionigi, Paolo

AU - Limonta, Giorgio

AU - Marelli, Marina

AU - Ciani, Isabella Besana

AU - Bianchi, Veronica

AU - Vanoli, Cristiana

AU - Dionigi, Renzo

PY - 2006/11

Y1 - 2006/11

N2 - During the recent years, based on the results of validation studies, the sentinel lymph node biopsy has replaced routine axillary dissection as the new standard of care in early breast cancer. The technique represents a minimally invasive, highly accurate method for axillary staging, which could spare approximately 65-70% of patients unnecessary axillary dissection and its related morbidity Several technical and clinical controversies have been raised during the development of this new technique; the authors review the most important issues, some questions have already been answered and others are still under debate. As far as the technical aspects are concerned, mapping techniques, appropriate surgical training, options for pathological examination of sentinel lymph nodes and the issue of nonaxillary sentinel lymph nodes are discussed. An update on clinical controversies demonstrates that factors such as large tumor size, palpable axillary nodes, multifocality and multicentricity, previous breast and axillary surgery, and pregnancy are no longer regarded as absolute contraindications for sentinel lymph node biopsy. Feasibility, accuracy and timing of sentinel lymph node biopsy in patients undergoing neoadjuvant chemotherapy remain unsolved issues, as well as the indication of the technique for some subgroups of in situ lesions. Finally, one of the most attractive open forums for debate will be discussed: Whether or not completion of axillary dissection in the case of positive SLN is always required.

AB - During the recent years, based on the results of validation studies, the sentinel lymph node biopsy has replaced routine axillary dissection as the new standard of care in early breast cancer. The technique represents a minimally invasive, highly accurate method for axillary staging, which could spare approximately 65-70% of patients unnecessary axillary dissection and its related morbidity Several technical and clinical controversies have been raised during the development of this new technique; the authors review the most important issues, some questions have already been answered and others are still under debate. As far as the technical aspects are concerned, mapping techniques, appropriate surgical training, options for pathological examination of sentinel lymph nodes and the issue of nonaxillary sentinel lymph nodes are discussed. An update on clinical controversies demonstrates that factors such as large tumor size, palpable axillary nodes, multifocality and multicentricity, previous breast and axillary surgery, and pregnancy are no longer regarded as absolute contraindications for sentinel lymph node biopsy. Feasibility, accuracy and timing of sentinel lymph node biopsy in patients undergoing neoadjuvant chemotherapy remain unsolved issues, as well as the indication of the technique for some subgroups of in situ lesions. Finally, one of the most attractive open forums for debate will be discussed: Whether or not completion of axillary dissection in the case of positive SLN is always required.

KW - Breast cancer

KW - Breast surgery

KW - Clinical controversies

KW - Sentinel node biopsy

KW - Sentinel node micrometastasis

KW - Technical controversies

UR - http://www.scopus.com/inward/record.url?scp=33750713330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750713330&partnerID=8YFLogxK

U2 - 10.1586/14737140.6.10.1503

DO - 10.1586/14737140.6.10.1503

M3 - Article

C2 - 17069533

AN - SCOPUS:33750713330

VL - 6

SP - 1503

EP - 1515

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 10

ER -